To hear about similar clinical trials, please enter your email below
Trial Title:
LAG3 Expression in Triple Negative Breast Cancer
NCT ID:
NCT06259162
Condition:
Triple Negative Breast Cancer
Immune Checkpoint Inhibitor
Conditions: Official terms:
Breast Neoplasms
Triple Negative Breast Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Screening
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
LAG-3 expression / immune checkpoint protein expression
Description:
Evaluate the tissue and blood before and after chemotherapy
Arm group label:
LAG-3 expression/immune checkpoint protein expression evaluation
Summary:
This study is the experimental study for relationship between LAG-3 expression / immue
checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint
inhibitor in triple negative breast cancer.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Planned neoadjuvant chemotherapy
- Triple negative breast cancer
Exclusion Criteria:
- HER2-positive breast cancer
- Hormone receptor positive breast cancer
Gender:
Female
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
Accepts Healthy Volunteers
Locations:
Facility:
Name:
Ji-Yeon Kim
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Ji-Yeon Kim
Start date:
November 18, 2022
Completion date:
December 31, 2027
Lead sponsor:
Agency:
Samsung Medical Center
Agency class:
Other
Source:
Samsung Medical Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06259162
